Fujairah Mountain Shooting Championship Returns for a New Edition in February 2025
The Fujairah Shooting Club announces the important dates, side events, ambassadors and launch of the website of the second edition of Fujairah Mountain Shooting Championship
Following the resounding success of its inaugural edition in 2023, Fujairah Shooting Club has announced the return of the Fujairah Mountain Shooting Championship (FMSC) and the launch of the championship's official website for its second edition. The unparalleled and challenging sporting event will return in February 2025 and will be held under the patronage of His Highness Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah.
The championship, which will run from February 1 to 8, 2025, in Dibba, Fujairah, UAE, will feature challenging layouts, exhilarating side events, and the chance to experience the natural beauty of the Emirate. The main championship, which will be held from February 5 to 8, will feature Super Sporting with 240 clays, a total prize of USD 300,000, and USD 50,000 for 100 flash clays.
The preliminary competitions of FMSC 2025 will be held from February 1 to 4 and will feature 50 clays of English Sporting with a total prize pool of USD 40,000 across four categories. The opening ceremony will be held on February 4, and the awards ceremony is scheduled for February 8, 2025.
The main championship will feature 24 stands, each equipped with six machines and presenting ten targets, including singles and doubles. Over the course of four days, 240 targets will be set, with 60 targets to be covered each day, and participants will be organised into six-man squads to compete throughout the event.
Saif Al Zahmi, Director, FMSC, said: “Held under the patronage of H.H. Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah, FMSC draws inspiration from the rich hunting tradition of the region and celebrate its enduring heritage. We are delighted to announce the launch of the website, kicking off the most anticipated return of the event with many new additions in February 2025. Moreover, it is a unique sporting event with over AED 1,000,000 in prizes and a chance to experience the region's vibrant culture. The competition, along with exciting side events, promises an exhilarating experience while respecting the environment through the use of ammunition with 100% natural biodegradable wads and eco-friendly clay targets suitable for all ages.”
One of the highlights of the 2025 edition is side events such as Pool Shoots and English Sporting, which will be held from February 1 to 7. Additionally, the latest edition of the championship is organised with the support of the National Sporting Clays Association and the Clay Pigeon Shooting Association, features George Digweed MBE, a renowned English sport shooter and multiple world and European clay-shooting champion; Phil Gray and Saif Bin Futtais, an Emirati sport shooter and five-time Olympian, as ambassadors.
For more information, visit fmsc.ae.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909161040/en/
Contacts
Tarek Kamal El Dine, +971 50 8829649
Tarek Kamal El Dine, +971 50 8829649
tarek@cpo.fujairah.ae
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom